
|Articles|April 1, 2001
- Pharmaceutical Executive-04-01-2001
- Volume 0
- Issue 0
Liberated?
Author(s)Wayne Koberstein
Patents before profits. That soundbite snagged my ears and turned my full attention to the CNN business report. I recognized the voice and the face}Ray Gilmartin, chairman of Merck. Calmly and reasonably, he explained how extraordinary circumstances in the developing world demand that his company uncouple the normally fused objectives of high profitability and unwavering patent protection.
Advertisement
Articles in this issue
over 25 years ago
Internet DTC - Minding Your P's & Q'sover 25 years ago
Regulation: Two-Track Planover 25 years ago
Policy: Tectonic Shiftover 25 years ago
A Matter of Tasteover 25 years ago
Partnerships: Bargaining Biotechsover 25 years ago
Pediatric Mandateover 25 years ago
Genentech's Passion for Patientsover 25 years ago
Regulation: OK After AllAdvertisement
Advertisement
Advertisement
Trending on PharmExec
1
How Exposed is The U.S. Pharmaceutical Supply Chain to China’s Updated Export Control Regulations?
2
Bristol Myers Squibb Expands Collaboration with Nvidia to Build AI Factory
3
Staying Ahead of Viral Evolution: Q&A with Robert Allen, Ph.D
4
Pharmaceutical Executive Daily: Bristol Myers Squibb Expands Partnership with Nvidia
5




